SHATTUCK LABS INC. - COMMON STOCK

Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 Nov 2024 06:00:01 By Nasdaq GlobeNewswire

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

01 Oct 2024 05:30:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights

01 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

30 Jul 2024 16:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

01 Jul 2024 05:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

14 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

10 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

06 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress

14 May 2024 15:15:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

02 May 2024 06:05:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

09 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

01 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

04 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

29 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Participation in Upcoming March Conferences

26 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

13 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

08 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

04 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

21 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients

13 Dec 2023 05:00:00 By Nasdaq GlobeNewswire